CO6602113A2 - Derivados de 3.4-dihidropirrolo[1.2-a]pirazina -2.8(1h)-dicarboxamida su preparación y su uso terapéutico - Google Patents
Derivados de 3.4-dihidropirrolo[1.2-a]pirazina -2.8(1h)-dicarboxamida su preparación y su uso terapéuticoInfo
- Publication number
- CO6602113A2 CO6602113A2 CO12218640A CO12218640A CO6602113A2 CO 6602113 A2 CO6602113 A2 CO 6602113A2 CO 12218640 A CO12218640 A CO 12218640A CO 12218640 A CO12218640 A CO 12218640A CO 6602113 A2 CO6602113 A2 CO 6602113A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- group
- therapeutic use
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos que responden a la fórmula general (I) en la que R2 representa un grupo alquilo-C1-10, cicloalquilo-C3-10, cicloalquil-C3-7-alquilo-C1-6, alquilo-C1-6-cicloalquilo-C3-7, cicloalquil-C3-7-cicloalquilo-C3-7, alquiltio-C1-6-alquilo-C1-10, alcoxi-C1-6-alquilo-C1-10, hidroxi-alquilo-C1-10, hidroxi-alquilC1-6-cicloalquil-C3-7-alquilo-C1-6, hidroxi-cicloalquilo-C3-10, fluoroalquilo-C1-10, fluorocicloalquilo-C3-10; un grupo heterocíclico sustituido opcionalmente; un grupo alquilo-C1-10 sustituido con un grupo heterocíclico sustituido opcionalmente; X6 representa un grupo elegido entre el átomo de hidrógeno, de flúor, de cloro o de bromo o un grupo alquilo-C1-6,cicloalquilo-C3-7, cicloalquil-C3-7-alquilo-C1-6, fluoroalquilo-C1-6 o ciano; y R7 representa un grupo arilo tal como fenilo o naftilo, sustituidos opcionalmente con uno o varios sustituyentes en el estado de base o de sal de adición a un ácido. Uso terapéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1054372A FR2960876B1 (fr) | 2010-06-03 | 2010-06-03 | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6602113A2 true CO6602113A2 (es) | 2013-01-18 |
Family
ID=42697541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12218640A CO6602113A2 (es) | 2010-06-03 | 2012-12-03 | Derivados de 3.4-dihidropirrolo[1.2-a]pirazina -2.8(1h)-dicarboxamida su preparación y su uso terapéutico |
Country Status (38)
Country | Link |
---|---|
US (2) | US8791119B2 (es) |
EP (1) | EP2588480B1 (es) |
JP (1) | JP5995841B2 (es) |
KR (1) | KR20130113928A (es) |
CN (1) | CN103168041B (es) |
AR (1) | AR081832A1 (es) |
AU (1) | AU2011268651B2 (es) |
BR (1) | BR112012030697A2 (es) |
CA (1) | CA2801154C (es) |
CL (1) | CL2012003360A1 (es) |
CO (1) | CO6602113A2 (es) |
CR (1) | CR20120595A (es) |
CY (1) | CY1118512T1 (es) |
DK (1) | DK2588480T3 (es) |
DO (1) | DOP2012000296A (es) |
EA (1) | EA201291364A1 (es) |
EC (1) | ECSP12012322A (es) |
ES (1) | ES2603420T3 (es) |
FR (1) | FR2960876B1 (es) |
GT (1) | GT201200319A (es) |
HR (1) | HRP20161494T1 (es) |
HU (1) | HUE030650T2 (es) |
IL (1) | IL223364A (es) |
LT (1) | LT2588480T (es) |
MA (1) | MA34360B1 (es) |
MX (1) | MX2012014084A (es) |
NI (1) | NI201200176A (es) |
NZ (1) | NZ603947A (es) |
PE (1) | PE20130259A1 (es) |
PL (1) | PL2588480T3 (es) |
PT (1) | PT2588480T (es) |
SG (1) | SG186143A1 (es) |
SI (1) | SI2588480T1 (es) |
TN (1) | TN2012000520A1 (es) |
TW (1) | TWI487707B (es) |
UY (1) | UY33428A (es) |
WO (1) | WO2011161537A2 (es) |
ZA (1) | ZA201209071B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
AR098414A1 (es) * | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
JP6307989B2 (ja) * | 2014-04-02 | 2018-04-11 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
EP3610040A1 (en) | 2017-04-12 | 2020-02-19 | H. Hoffnabb-La Roche Ag | A method for sequencing reaction with tagged nucleoside obtained via pictet spengler reaction |
KR20200032702A (ko) * | 2017-07-27 | 2020-03-26 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피페라진 헤테로아릴 유도체, 그 제조 방법 및 의약에서 이의 용도 |
TW202412758A (zh) * | 2022-06-29 | 2024-04-01 | 香港商英矽智能科技知識產權有限公司 | Fgfr2與fgfr3抑制劑及其用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1150991B1 (en) | 1999-02-01 | 2004-04-07 | University of Virginia Patent Foundation | Compositions for treating inflammatory response |
MXPA04002243A (es) * | 2001-09-19 | 2004-06-29 | Aventis Pharma Sa | Compuestos quimicos. |
GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
US7402672B2 (en) | 2003-12-11 | 2008-07-22 | Aventis Pharmaceuticals Inc. | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon |
GB0328900D0 (en) | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
WO2008147713A1 (en) * | 2007-05-24 | 2008-12-04 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
CA2694288A1 (fr) * | 2007-07-27 | 2009-04-09 | Sanofi-Aventis | Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamides, leur preparation et leur application en therapeutique |
CA2712265A1 (en) * | 2008-01-17 | 2009-07-23 | Gruenenthal Gmbh | Substituted sulfonamide derivatives |
US20090192147A1 (en) * | 2008-01-30 | 2009-07-30 | Wyeth | [a]-FUSED INDOLE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES |
FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
-
2010
- 2010-06-03 FR FR1054372A patent/FR2960876B1/fr not_active Expired - Fee Related
-
2011
- 2011-06-01 KR KR1020127031424A patent/KR20130113928A/ko active Search and Examination
- 2011-06-01 SG SG2012088795A patent/SG186143A1/en unknown
- 2011-06-01 PL PL11781590T patent/PL2588480T3/pl unknown
- 2011-06-01 MX MX2012014084A patent/MX2012014084A/es active IP Right Grant
- 2011-06-01 MA MA35524A patent/MA34360B1/fr unknown
- 2011-06-01 EA EA201291364A patent/EA201291364A1/ru unknown
- 2011-06-01 LT LTEP11781590.2T patent/LT2588480T/lt unknown
- 2011-06-01 AU AU2011268651A patent/AU2011268651B2/en not_active Ceased
- 2011-06-01 SI SI201131022A patent/SI2588480T1/sl unknown
- 2011-06-01 WO PCT/IB2011/001594 patent/WO2011161537A2/en active Application Filing
- 2011-06-01 PE PE2012002257A patent/PE20130259A1/es not_active Application Discontinuation
- 2011-06-01 NZ NZ603947A patent/NZ603947A/en not_active IP Right Cessation
- 2011-06-01 BR BR112012030697A patent/BR112012030697A2/pt not_active IP Right Cessation
- 2011-06-01 PT PT117815902T patent/PT2588480T/pt unknown
- 2011-06-01 EP EP11781590.2A patent/EP2588480B1/en active Active
- 2011-06-01 JP JP2013513006A patent/JP5995841B2/ja not_active Expired - Fee Related
- 2011-06-01 CN CN201180038277.8A patent/CN103168041B/zh not_active Expired - Fee Related
- 2011-06-01 CA CA2801154A patent/CA2801154C/en not_active Expired - Fee Related
- 2011-06-01 DK DK11781590.2T patent/DK2588480T3/en active
- 2011-06-01 HU HUE11781590A patent/HUE030650T2/en unknown
- 2011-06-01 ES ES11781590.2T patent/ES2603420T3/es active Active
- 2011-06-02 AR ARP110101901A patent/AR081832A1/es not_active Application Discontinuation
- 2011-06-03 UY UY0001033428A patent/UY33428A/es unknown
- 2011-06-03 TW TW100119696A patent/TWI487707B/zh not_active IP Right Cessation
-
2012
- 2012-10-31 TN TNP2012000520A patent/TN2012000520A1/en unknown
- 2012-11-22 DO DO2012000296A patent/DOP2012000296A/es unknown
- 2012-11-26 CR CR20120595A patent/CR20120595A/es unknown
- 2012-11-27 GT GT201200319A patent/GT201200319A/es unknown
- 2012-11-29 IL IL223364A patent/IL223364A/en not_active IP Right Cessation
- 2012-11-29 US US13/688,916 patent/US8791119B2/en not_active Expired - Fee Related
- 2012-11-30 CL CL2012003360A patent/CL2012003360A1/es unknown
- 2012-11-30 ZA ZA2012/09071A patent/ZA201209071B/en unknown
- 2012-11-30 NI NI201200176A patent/NI201200176A/es unknown
- 2012-12-03 EC ECSP12012322 patent/ECSP12012322A/es unknown
- 2012-12-03 CO CO12218640A patent/CO6602113A2/es active IP Right Grant
-
2014
- 2014-07-23 US US14/339,112 patent/US9233965B2/en not_active Expired - Fee Related
-
2016
- 2016-11-11 HR HRP20161494TT patent/HRP20161494T1/hr unknown
- 2016-11-16 CY CY20161101179T patent/CY1118512T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6602113A2 (es) | Derivados de 3.4-dihidropirrolo[1.2-a]pirazina -2.8(1h)-dicarboxamida su preparación y su uso terapéutico | |
AR101820A1 (es) | Difluorometil-indanil-carboxamidas nicotínicas | |
CO6592042A2 (es) | Derivados de n3-sustituido -n1-sulfonil-5-fluorpirimidinona | |
CO6741198A2 (es) | Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos | |
PE20151606A1 (es) | DERIVADOS DE NAFTIRIDINA UTILES COMO ANTAGONISTAS DE LA AvB6 INTEGRINA | |
PE20130779A1 (es) | Pirimidinas y triazinas condensadas y su uso | |
IN2015DN01315A (es) | ||
CR20130349A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H- INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III | |
AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
EA201100037A1 (ru) | Органические соединения | |
CO6640226A2 (es) | 5-fluoro-1h-pirazolipiridinas sustituidas y su uso | |
CO6491116A2 (es) | Derivados de 5-fluoropirimidinona | |
CL2011002825A1 (es) | Compuestos derivados de bencimidazol heteroarilo sustituido; composición farmacéutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
CU20140110A7 (es) | Compuestos heterocíclicos como inhibidores de mek | |
CR20140217A (es) | Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas ii | |
ES2601956T3 (es) | Composición para batería de litio que comprende al menos un compuesto de flúor específico como disolvente orgánico y al menos una sal de litio | |
JP2015518492A5 (es) | ||
PE20170683A1 (es) | Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2 | |
PE20160039A1 (es) | NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA | |
NI201200019A (es) | Derivados de 5 - fluoro - 2 - oxopirimidina - 1(2h) - carboxilato | |
ECSP12011652A (es) | Derivados de 5-fluoro-2-oxopirimidinona-1 (2h)-carboxamida substituida-n1 | |
AR083301A1 (es) | Uso de composiciones de halogeno organico para reducir las emisiones de mercurio durante la combustion de carbon | |
PE20160125A1 (es) | Pirazolpiridinas sustituidas | |
RS54689B1 (en) | CONNECTED BICYCLIC 2,4- DIAMINOPYRIMIDINE DERIVATIVE AS DUAL ALK AND FAK INHIBITOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |